According to company sources, Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company has its main manufacturing facility in Brehna near Leipzig. Its integrated business model comprises in-house development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets via a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorisations for more than 200 active pharmaceutical ingredients. In addition to Germany, the company's core markets also include Austria and Switzerland; it is planning to further expand its international presence. Dermapharm's business model also includes a parallel import business, which operates under the 'axicorp' brand.

Deutsche Börse AG published this content on 09 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 09 February 2018 09:15:03 UTC.

Original documenthttp://deutsche-boerse.com/dbg-en/media-relations/press-releases/First-IPO-of-the-year--family-owned-Dermapharm-listed-today-on-the-Frankfurt-Stock-Exchange/3323440

Public permalinkhttp://www.publicnow.com/view/E1AD87A0339F9AA90E4E6720C292151147710387